MCI 225
Alternative Names: AA 10021; AA 10025; AA 10026Latest Information Update: 02 Apr 2008
At a glance
- Originator Mitsubishi Chemical
- Developer Arachnova
- Class Analgesics; Antidepressants; Irritable bowel syndrome therapies; Nootropics; Pyrimidines; Small molecules; Urologics
- Mechanism of Action Adrenergic receptor antagonists; Serotonin 3 receptor antagonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Irritable bowel syndrome; Pain; Stress incontinence
Most Recent Events
- 01 Oct 2007 Mitsubishi Pharma Corporation merged with Tanabe Seiyaku Co. Ltd to form Mitsubishi Tanabe Pharma Corporation
- 24 Jul 2006 This compound is in active development for Pain, Stress incontinence and Irritable bowel Syndrome
- 22 Jan 2003 Preclinical trials in Pain in United Kingdom (unspecified route)